Myriad Genetics First Quarter 2024 Financial Earnings

Tuesday, May 7, 2024 | 1:30pm PST / 4:30pm EST

Watch the webcast Download presentation

Events & Presentations

  • 45th Annual Global Goldman Sachs Global Healthcare Conference

    06/12/2024 | 12:20pm PDT / 3:20pm EDT

  • Leerink Partners Healthcare Crossroads Conference

    05/30/2024 | 8:00am PDT / 11:00am EDT

    Watch the webcast

  • Piper Sandler Virtual Cancer Testing Day

    05/21/2024 | 8:00am PDT / 11:00am EDT

View all events

Financial Reports and Filings

Date Filing Title Downloads
05/15/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
05/15/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
05/15/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
05/14/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
05/13/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
05/13/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
05/08/2024 10-Q Quarterly report which provides a continuing view of a company's financial position RTF XLS PDF HTML XBRL
05/07/2024 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
05/01/2024 SC 13G A statement of beneficial ownership of common stock by certain persons RTF XLS PDF HTML XBRL
04/25/2024 SC 13G A statement of beneficial ownership of common stock by certain persons RTF XLS PDF HTML XBRL
View all filings

Latest News

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer Thumbnail

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

May 16, 2024 | Products

Read more
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Thumbnail

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

May 07, 2024 | Corporate | Financial

Read more
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business Thumbnail

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

May 07, 2024 | Products | Corporate

Read more
View all news releases

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics